Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results
Date:3/3/2010

"2009 was a tremendous year for Jazz Pharmaceuticals in continuing our mission to help improve patients' lives.  Our sales team delivered outstanding performance in 2009, educating physicians on the appropriate use of our products, which resulted in records for prescriptions of both XYREM and LUVOX CR," said Bob Myers, President of Jazz Pharmaceuticals.

Research and development expenses for the quarter ended December 31, 2009 were $6.3 million, compared to $14.7 million for the quarter ended December 31, 2008.  For the year ended December 31, 2009, research and development expenses were $36.6 million, compared to $70.0 million for the year ended December 31, 2008.  Research and development expenses in both 2009 and 2008 primarily reflect the expenses relating to Phase III clinical activities for the company's JZP-6 product candidate, sodium oxybate for the treatment of fibromyalgia.  In 2009, the company completed the second of two Phase III clinical studies and submitted a New Drug Application (NDA) for JZP-6 to the U.S. Food and Drug Administration (FDA) in December.  The NDA for JZP-6 was filed by the FDA in February 2010 and the target date for the FDA to complete its review under the Prescription Drug User Fee Act (PDUFA) is Oct
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  Medical Science Liaisons play ... key link between the medical device industry and key ... in the coming years as the device industry relies ... According to research by benchmarking firm, Best Practices, LLC, ... an important edge is by harnessing new technology to ...
(Date:12/22/2014)... Calif. , Dec. 22, 2014 Apnea ... expanded corporate offices in Aliso Viejo ... that due to the tremendous growth and worldwide expansion, ... Sales of patented SnoreRx, the anti snore cure have ... He said, "We are now in 23 countries ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2Investment Analysis of the US Medical Device Sector 2
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
(Date:12/25/2014)... The short film “Color of Honor” by young ... a true 9/11 hero, Welles Remy Crowther. It has been ... hours of Nuremberg International Short Film Festival and the 8th ... screenwriter and director Luciana Lagana plays the mother of ... husband, Gregory Graham - Graham plays a heroic ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping ... of the models at LunaDress.co.uk come with big discounts, up to ... veil can turn out to be a most exciting memory and ... always bring surprise to a wedding. On the updated fashion blog, ... veils for a big day . , Going out with friends ...
(Date:12/25/2014)... By Dennis Thompson ... -- Researchers could be closing in on a "fountain of ... improve the health of older adults, a new study suggests. ... when given a drug that targets a genetic signaling pathway ... maker Novartis report. The experimental medication, a ...
(Date:12/25/2014)... Newton, North Carolina (PRWEB) December 25, 2014 ... a North Carolina Retirement Community, recently showed their ... and girls of the Catawba County Parenting Network- ... meal, the 10 children gathered around the largest ... community to open presents purchased by residents of ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2
... Ellsworth ... line. , ... Germantown, WI (PRWEB) June 19, 2010 -- Ellsworth Adhesives announced today it has ... Seal® line offers high-performance, flexible, chemical resistant sealants that are designed for a variety ...
... ... , ... June 19, 2010 -- Steri-7(TM) a privately held UK company with a broad product line ... care and related industries announced today that Dr Andy Kielbania Chief Scientist at BioNeutral Group ...
... For healthcare professionals diagnosing primary Sjgren,s Syndrome (pSS, an ... moisture-producing glands), the incidence of blood based deficiencies is ... according to the results of a study presented today ... League Against Rheumatism in Rome, Italy. The study also ...
... ... for Someone Who Can Turn Simple Dishes in to Super Meals , ... Pompano Beach, FL (PRWEB) June 18, 2010 -- ... are challenging America to get creative with shelf-stable seafood in a search for the Chicken ...
... than 20 percent of deaths in a study of 12,000 ... new research reports. The large 10-year study is ... to arsenic and its associated mortality risk, the authors said. ... York, and Bangladesh, will be published early online Saturday in ...
... ... and dedication among healthcare professionals. This awards program salutes the individual health ... and the patients and family members they serve in every sector of ... National Press Club in Washington, D.C., on October 4, where the award ...
Cached Medicine News:Health News:Ellsworth Adhesives Is Adding PRC Rapid Seal Product Line Offering 2Health News:Steri -7 Appoints BioNeutral Group Inc. Chief Scientist Dr. Andy Kielbania for Expanded Role 2Health News:Blood deficiencies are strong predictors of poor outcome 2Health News:'The Balancing Act' & Chicken of the Sea Search for America's 'Supercook' 2Health News:'The Balancing Act' & Chicken of the Sea Search for America's 'Supercook' 3Health News:Deadly effect of arsenic in drinking water measured in massive study 2Health News:Deadly effect of arsenic in drinking water measured in massive study 3Health News:Dorland Health People Awards Accepting Entries through Friday, June 25, 2010 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: